Latest news with #HPV-negative
Yahoo
12-06-2025
- Health
- Yahoo
NHS makes major change to cervical cancer screenings for younger women
Women aged 25 to 49 who test negative for human papillomavirus (HPV) will be invited to cervical screening every five years instead of every three, under new NHS guidelines. The change, set to take effect next month in England, follows recommendations from the UK National Screening Committee. According to analysis from King's College London, extending the screening interval to five years for HPV-negative women is just as safe as the current three-year interval, with a similar rate of cancer detection. HPV is a sexually transmitted group of viruses, with around 13 high-risk types known to cause almost all cases of cervical cancer. Most people with HPV don't experience any symptoms. Women who test positive for HPV, or have a history of the virus, will continue to be invited for more frequent screenings to monitor the virus and check for any changes to cells in the cervix. In a written statement to Parliament, health minister Ashley Dalton said the new change 'increases the opportunities to test and recall women and people with a cervix who have HPV, while extending the cervical screening intervals from three to five years in England for individuals who have a negative HPV test. 'This will bring England's cervical screening intervals in line with those of Wales and Scotland.' She said the NHS screening programme in England provides all women between the ages of 25 and 64 'with the opportunity to be screened routinely to detect HPV infection or cervical abnormalities at an early, more treatable stage'. She added: 'The aim of the programme is to reduce the number of women who develop invasive cervical cancer and reduce the number who die from it.' Ms Dalton said testing negative for HPV means the chances of developing cancer within five years are very small, as it can take around 10 years or more from the time HPV is detected to developing cervical cancer. She added: 'Those who test positive for HPV are already being followed up with yearly testing. 'This is important to ensure that individuals are monitored for any early signs of cervical abnormalities and provided the necessary treatment.' Experts have been concerned about falling numbers of women under 50 attending cervical screening, with around a third in England not taking up their invitations. Dr Sue Mann, NHS national clinical director for women's health, said: 'Taking a more personalised approach to cervical screening will help ensure everyone eligible can make the most of these life-saving services, while sparing women appointments that they don't need. 'The NHS is following robust evidence on how often women need to be safely screened, and by putting invitations and reminders straight in women's pockets on their phones, we're making it easier than ever to take up screening appointments. 'Make sure you come forward for your screening when you're invited, even if it was weeks, months or years ago. If you think you are due but have not yet had an invitation, speak to your GP practice.' Michelle Mitchell, chief executive of Cancer Research UK, said: 'We welcome this change to cervical screening in England, which is the result of years of vital research to make screening more effective and has shown it is safe to extend the time between tests. 'Screening, alongside the roll out of the HPV vaccine – which Cancer Research UK scientists helped develop – have seen cervical cancer rates drop by around a quarter since the early 1990s, and we look forward to even more progress. 'If you notice any unusual changes for you, do not wait for a screening invitation – speak to your doctor.' Athena Lamnisos, chief executive of the Eve Appeal, said: 'We want every eligible person to feel empowered to attend a vaccination and cervical screening appointment when they are invited so we can achieve the brilliant ambition of eliminating cervical cancer.'
Yahoo
03-06-2025
- Business
- Yahoo
Transgene to Host Webcast on Positive TG4050 Head and Neck Cancer Data Presented at ASCO 2025
Strasbourg (France), June 3, 2025, 8:00 a.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today announced it will host a live webcast to discuss the latest positive clinical data from its individualized neoantigen cancer vaccine, TG4050, presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting (see press release here). The webcast will take place on June 6, 2025 at 9:00 a.m. ET / 3:00 p.m. CET, and will feature Transgene's management together with Prof. Christian Ottensmeier, MD, PhD, FRCP (University of Liverpool, La Jolla Institute for Immunology). They will discuss the new findings, the unmet medical need and the current treatment landscape and perspectives for early-stage HPV-negative head and neck cancer. Webcast link to English language conference call: Please log in to the following link to obtain your personal telephone IDs: A replay of the call will be available on the Transgene website ( following the live event. *** About TransgeneTransgene (Euronext: TNG) is a biotechnology company focused on designing and developing targeted immunotherapies for the treatment of cancer. The Company's clinical-stage programs consist of a portfolio of viral vector-based immunotherapeutics. TG4050, the first individualized therapeutic vaccine based on the myvac® platform is the Company's lead asset, with demonstrated proof of principle in patients in the adjuvant treatment of head and neck cancers. The portfolio also includes other viral-vector-based immunotherapies: TG4001 for the treatment of HPV-positive cancers, as well as BT-001 and TG6050, two oncolytic viruses based on the viral backbone. The Company also conducts innovative discovery and preclinical work, aimed at developing novel viral vector-based modalities. With Transgene's myvac® platform, therapeutic vaccination enters the field of precision medicine with a novel immunotherapy that is fully tailored to each individual. The myvac® approach allows the generation of a virus-based immunotherapy that encodes patient-specific mutations identified and selected by Artificial Intelligence capabilities provided by its partner its proprietary platform Transgene is building on its viral vector engineering expertise to design a new generation of multifunctional oncolytic information about Transgene is available at: us on social media: X (formerly Twitter): @TransgeneSA — LinkedIn: @Transgene — Bluesky: @Transgene Contacts Media: Investors & Analysts: Caroline Tosch Lucie Larguier Corporate and Scientific Communications Manager Chief Financial Officer (CFO) +33 (0)3 68 33 27 38 Nadege Bartoli communication@ Investor Relations Analystand Financial Communications Officer MEDiSTRAVA +33 (0)3 88 27 91 00/03 Frazer Hall/Sylvie Berrebi investorrelations@ + 44 (0)203 928 6900 transgene@ DisclaimerThis press release contains forward-looking statements, which are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. The occurrence of any of these risks could have a significant negative outcome for the Company's activities, perspectives, financial situation, results, regulatory authorities' agreement with development phases, and development. The Company's ability to commercialize its products depends on but is not limited to the following factors: positive pre-clinical data may not be predictive of human clinical results, the success of clinical studies, the ability to obtain financing and/or partnerships for product manufacturing, development and commercialization, and marketing approval by government regulatory authorities. For a discussion of risks and uncertainties which could cause the Company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors ('Facteurs de Risque') section of the Universal Registration Document, available on the AMF website ( or on Transgene's website ( Forward-looking statements speak only as of the date on which they are made, and Transgene undertakes no obligation to update these forward-looking statements, even if new information becomes available in the future. Attachment 20250603_Transgene_Webcast_ENError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
29-05-2025
- Business
- Yahoo
Morgan Stanley Maintains Buy Rating on Bicara (BCAX) After the Ficerafusp Alfa Trial Update
On May 23, Judah Frommer from Morgan Stanley maintained a Buy rating on Bicara Therapeutics Inc. (NASDAQ:BCAX) while keeping the price target at $36. This comes after the company released its interim data from Phase 1/1b trial of Ficerafusp alfa, which is the company's lead asset and a first-in-class bifunctional antibody. Close-up of a scientist in a lab conducting tests on a humanized immunoglobulin G1. Bicara Therapeutics Inc. (NASDAQ:BCAX) is a clinical-stage biopharmaceutical company that develops innovative bifunctional antibody therapies for solid tumors. Ficerafusp alfa is being tested for enhanced tumor penetration and to overcome the immunosuppressive tumor microenvironment, which has historically limited treatment efficacy in solid tumors. The recent data from the Phase 1/1b study has shown promising results in treating HPV-negative patients who have head and neck squamous cell carcinoma. The analyst highlighted that the trial reported a median overall survival exceeding 20 months, including an 18-21% complete response rate. Frommer believes this is a significant improvement compared to standard care, suggesting that approval of Ficerafusp alfa could be a breakthrough in a challenging therapeutic area. While we acknowledge the potential of BCAX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than BCAX and that has 100x upside potential, check out our report about the . READ NEXT: and . Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
26-05-2025
- Business
- Yahoo
Stifel Reaffirms Buy Rating on BCAX After Promising ASCO Data for HPV-Negative Patients
On May 24, analysts at Stifel reaffirmed their Buy rating and price target of $48 for Bicara Therapeutics Inc. (NASDAQ:BCAX). This follows the American Society of Clinical Oncology (ASCO) releasing abstracts after the market's close, which sparked debates regarding competing approaches to treating 1L SCCHN. The company's abstract provided a number of encouraging results for HPV-negative patients. These included an improved complete response (CR) rate, currently at 21%, a 12-month duration of response and overall survival (OS) of 60/61%, alongside a median overall survival (mOS) of more than 20 months. However, analysts pointed out that Merus, a market rival, also provided impressive full ASCO data that included both HPV-positive and HPV-negative patients. That said, Stifel analysts cautioned that it may be unreliable to draw competitive conclusions from non-randomized patient groups. In light of this, Stifel advises investors to purchase BCAX stock on any price weakness and to wait for more thorough information from Bicara at the next ASCO meetings. While we acknowledge the potential of BCAX to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than BCAX and that has 100x upside potential, check out our report about the cheapest AI stock. Read More: and . Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Insider
23-05-2025
- Business
- Business Insider
Bicara Therapeutics publishes updated data from Phase 1/1b trial of Ficerafusp
The company states: 'Bicara Therapeutics (BCAX) announced the publication of an abstract with updated interim data from the company's Phase 1/1b clinical trial of ficerafusp alfa in combination with pembrolizumab in patients with first line recurrent/metastatic head and neck squamous cell carcinoma on the 2025 American Society of Clinical Oncology Annual Meeting website. The company will host a conference call on Sunday, June 1, 2025 at 3:00 p.m. CT / 4:00 p.m. ET to present the fulsome dataset, including overall survival and duration of response data, following an oral presentation of the data at the ASCO Annual Meeting. Ficerafusp alfa is a first-in-class bifunctional antibody designed to enhance tumor penetration by breaking barriers within the tumor microenvironment that have challenged the treatment of multiple solid tumor cancers. Specifically, ficerafusp alfa combines two clinically validated targets: an epidermal growth factor receptor directed monoclonal antibody with a domain that binds to human transforming growth factor beta.' 'We are pleased to present the fulsome dataset from our Phase 1/1b trial of ficerafusp alfa in patients with recurrent/metastatic head and neck squamous cell carcinoma during our upcoming oral presentation at ASCO,' said David Raben, MD, Chief Medical Officer of Bicara Therapeutics. 'The interim data featured in the ASCO abstract demonstrate encouraging signals that represent a meaningful improvement over historical benchmarks in patients with HPV-negative disease, a population with high unmet need and worse survival outcomes than those with HPV-positive disease. Notably, we're encouraged to see how ficerafusp alfa, specifically designed to drive tumor penetration within the tumor microenvironment, is leading to deep, and now, durable responses that appear to be translating to prolonged overall survival.'
